Last updated: 2026-09-09 05:06:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aldeyra Therapeutics, Inc. (ALDX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.55, with a market capitalisation of $89.28M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.07 to $5.93. This page covers its latest market performance, valuation, price trends and company information.
$89.28M | |
$1.47 | |
$16.70 | |
$1.07 | |
$1.48 | |
705.81K | |
1.26M | |
-- | |
$5.93 | |
$1.07 | |
-- | |
-- |
Aldeyra Therapeutics, Inc. (ALDX) last closed at $1.48 as of 2026-09-08 23:31:00, unchanged from the previous close of $1.48.
During the latest regular trading session, ALDX traded between $1.07 and $16.70, with a volume of 705.81K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Aldeyra Therapeutics, Inc. (ALDX) moved from $1.54 to $1.55, representing a gain of 0.32% ($0.00).
The stock traded between $1.45 and $1.58 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 476.75 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.8%
ALDX is currently trading at $1.55, placing it 9.8% of the way from its 52-week low of $1.07 to its 52-week high of $5.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aldeyra Therapeutics, Inc. (ALDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.